

BUILDING AN INNOVATIVE PIPELINE IN ONCOLOGY & NEUROLOGY

Irene Blat, Head of External Innovation, North America
AUTM Connect & Collaborate, November 2025

SERVIER 
moved by you

DISCLAIMER

This document contains general information about the Servier Group and its legal entities (hereinafter “Servier and its Affiliates”) and is intended for informational purposes only. The information is thought to be reliable; however, Servier and its Affiliates make no representation as to the accuracy or completeness of the information contained herein or otherwise provided and accept no responsibility or liability, in contract, in tort, in negligence, or otherwise, should the information be found to be inaccurate or incomplete in any respect.

Servier and its Affiliates are not acting as an advisor to the recipient of this information, and the ultimate decision to proceed with any transaction rests solely with the recipient of this information. Therefore, prior to entering into any proposed transaction, the recipient of this information should determine, without reliance upon Servier or its Affiliates, the economic risks and merits, as well as the legal, tax, and accounting characterizations and consequences, of the transaction and that it is able to assume these risks.

Any reliance placed on this document is done entirely at the risk of the person placing such reliance. The information contained in this document is neither an offer to sell nor the solicitation of an offer to enter into a transaction.

The content of this document is a summary only, is not deemed to be comprehensive, and does not include all material information about Servier and its Affiliates.

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates disclaim all representations, warranties, conditions and guarantees, whether express, implied, statutory or of other kind, nor do they accept any duty to any person, in connection with this document. Without prejudice to the generality of the foregoing, Servier and its Affiliates do not warrant or represent that the information or opinions contained in this document are accurate or comprehensive.

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates shall not be liable for any loss, damage or expense whatsoever, whether direct or indirect, howsoever arising, whether in contract, tort (including negligence), strict liability or otherwise, for direct, indirect, incidental, consequential, punitive or special damages arising out of or in connection with this document, including (without limitation) any course of action taken on the basis of the same.

The estimates, strategies, and views expressed in this document are based upon past or current data and information and are subject to change without notice.



AMBITIOUS STRATEGY, STRONG FINANCIAL RESOURCES

Governed by Foundation: long term & independent



A RELIABLE, LONG-TERM PARTNER

Interested in assets from late research through to late clinical



TRACK RECORD OF SUCCESS

In building our oncology pipeline but now also focused on partnering in rare neurological disorders



PATIENTS AT THE HEART OF EVERYTHING WE DO

Innovating for the benefit of patients



SERVIER

moved by you

Your strategic partner

We are a private, midsize pharmaceutical company, owned by a foundation.

Our independence enables a long-term vision and gives us the freedom to make our own strategic decisions.

We are committed to therapeutic progress to service patient needs and driven by a bold ambition to double our revenue by 2030 by reaching €10 billion in sales.

We are present in all the key innovation ecosystems in the world with capabilities ranging from R&D, commercial and manufacturing.

This includes 4 R&D centers, 15 clinical development centers, 14 manufacturing sites and commercial capabilities across the globe.

We are convinced that combining internal and external innovation will enable us to respond to major therapeutic challenges.

3

HUBS (North and South America, Europe, Asia-Pacific)

4

RESEARCH CENTERS

15

DEVELOPMENT CENTERS

14

PRODUCTION SITES

22k

EMPLOYEES

DISCOVER OUR AREAS OF FOCUS FOR PARTNERING



Oncology



Neurology



Therapeutic modalities & technologies



Drug discoveries & development technologies




AI & digital technologies applied to R&D



Digital, Data, AI & Beyond-the-Pill

SERVIER'S ONCOLOGY FOCUS

Expanding our oncology pipeline to meet patient needs



RARE NEUROLOGICAL DISORDERS

Building on our successful approach in oncology

FOCUS AREAS



RARE MOVEMENT DISORDERS¹
FA, SCA, MSA, PSP, HD



NEUROMUSCULAR DISORDERS²
ALS, SMA, DMD, FSHD, DM, MG



REFRACTORY EPILEPSIES³
DS, LGS, JS, WS, OTHER DEES



LEUKODYSTROPHIES



GENETICALLY DRIVEN ASD⁴
PMD, RETT, AG



PERIPHERAL NEUROPATHIES⁵
CMT, CIDP

MODALITIES



OLIGONUCLEOTIDES



SMALL MOLECULES



ANTIBODIES



FUTURE GROWTH DRIVER

Building a sustainable rare neurology franchise by 2030



TARGETED

Rare, well-defined small patient populations with high unmet need



PATIENT LED

Deliver transformative medicines addressing rare, highly debilitating neurological disorders



LOOKING FOR PARTNERSHIPS

Ready to transact – track record in oncology shows ability to move swiftly and decisively

1. FA: Friedreich Ataxia; SCA: Spinocerebellar Ataxia; MSA: Multiple system Atrophy; PSP: Progressive Supranuclear Palsy; HD: Huntington Disease

2. ALS: Amyotrophic Lateral Sclerosis; SMA: Spinal Muscular Atrophy; DMD: Duchene Muscular Atrophy; FSHD: Fascioscapulohumeral Dystrophy; DM: Myotonic Dystrophy; MG: Myasthenia Gravis

3. DS: Dravet Syndrome; LGS: Lennox-Gastaut Syndrome; JS: Jeavons Syndrome; WS: West Syndrome; DEE: Developmental and Epileptic Encephalopathies

4. ASD: Autism Spectrum Disorders; PMD: Phelan McDermid Syndrome; AG: Angelman Syndrome

5. CMT: Charcot-Marie-Tooth; CIDP: Chronic Inflammatory Demyelinating Polyneuropathy

DISCOVER OUR AREAS OF FOCUS FOR PARTNERING

Therapeutic modalities & technologies



PARTNERING INTERESTS

Small Molecules

- Kinase, PPI, Receptor modulators; Molecular Glues, Bifunctional molecules, Small molecule targeting RNA for targeted protein degradation/upregulation
- Targeted delivery: prodrugs/polymer drug conjugates/targeted Lipid Nano Particles, Exosomes, Extracellular Vesicles
- Compound Library

Oligonucleotides

- Novel Monomers, Antisense Oligonucleotide (ASO) design technologies, ASO-conjugates and drug delivery systems, targeted saRNA, selective cell ligand targeting for neuronal cell delivery
- Oligo-Manufacturing

Antibodies

- Novel Formats: Ab Fragments, Single Domain Antibodies, Bi-/ Multi-specifics, optimized Fc domains
- Novel technology platform for Antibody Hard-to-Drug targets
- Synthetic antibody libraries
- ADCs linkage Chemistry/ Conditionally active antibody format

Drug discovery & development technologies



PARTNERING INTERESTS

Phenotypic cell platforms & 3D models

- iPSCs, patient derived models
- Co-culture models
- Organoids, tumoroids (PDAC, CRC, other solid tumors)
- Organ on a chip (liver, brain, kidney)

Protein sciences imaging

- High throughput functional & stability antibody screening
- Antigen specific immuno-oncology assays
- Microfluidic or micro array technology B-cell workflow
- Multi-protein production
- High throughput mass spectrometry based proteomic analysis approach
- Mass spectrometry target

Imaging

- High content imaging (tissues/cells) and analysis
- Multimodal platforms -multiplexing, spatial multiomics strategy, spatial phenotypic quantification
- In vivo visualization of antisense oligonucleotides (ASO) biodistribution
- ASO tolerability assays

Sample optimization

- Universal sample preparation
- Laser Capture Microdissection
- Single cell analysis ATAC (Assay for Transposase Accessible Chromatin)
- High throughput Mass Spectrometry based proteomic analysis approach

Liquid Biopsies

- Circulating tumor DNA (ctDNA) and methylation assay development
- Circulating tumor cells (CTC)
- Exosomes or extracellular vesicle extraction from blood for biomarker identification
- Technology to improve sensitivity
- Computational methods for Next-Generation Sequencing

Flow chemistry

- Multistep synthesis
- Photochemistry, electrochemistry
- Automation of downstream process (quenching, phase separation, distillation)
- Continuous crystallisation/drying/milling
- In line analysis
- Continuous manufacturing in pharma

DISCOVER OUR AREAS OF FOCUS FOR PARTNERING

AI & digital technologies applied to R&D



PARTNERING INTERESTS

Focusing on a patient-centered use of AI and digital technologies to:

- Enrich our pipeline by either developing first in class new drugs or by repurposing existing drugs
- Improve treatment effectiveness, reduce adverse effects and enhance patient outcomes
- Accelerate our drug discovery & development processes

Therapeutic modalities:

- Small molecules, antisense oligonucleotides (ASO), antibodies (mAbs, bispecifics, ADCs)

Main thematic of our data analytics strategy:

Early research

- Target identification and validation, hit screening and validation, drug design, patient stratification

Late research

- Treatment understanding, DMTA cycle optimization, disease understanding, biomarker identification

Early development

- Disease modelling, optimization of clinical trial design, biomarker validation

- Drug product development & characterization

Late development

- Strategy for patient finding and site selection, optimization of medical authoring, patient-centric clinical trial execution, pharmacovigilance processes optimization

Digital, Data, AI opportunities & Beyond-the-Pill solutions



PARTNERING INTERESTS

Preferred digital & AI use cases

Initiatives focusing pharma operational efficiency & decision-making

- AI medical, health equity and patient insights management
- Sales forecasts, supply chain, manufacturing & employee optimization

Examples of solutions supporting health care professional (HCPs) activities

- Clinical decision support tools and clinical trials platform optimization
- Remote patient monitoring & dashboards

Examples of beyond-the-pill solutions supporting patients & caregivers

- Solutions supporting adherence (esp. chronic disease) & quality of life
- Patients journey insights and personalization (esp. oncology)
- Solutions offering education and gamification possibilities


Preferred modalities

Deal types


- Co-development, licenses, strategic partnerships & beyond

Preferred maturity stage & technical aspects

- Ready to use solutions
- Previous pharma partnerships
- Medical device (depending on use case)
- Clinical benefits targeted



LET'S CONNECT!



Discover our partnering interests:
<https://servier.com/en/partnering/>

Download the brochure and find your contact:
<https://servier.com/wp-content/uploads/2025/06/servier-partnering-brochure.pdf>

